Saturday 17 October 2026 Export BTTX’s income statement to Excel — free account

Better Therapeutics, Inc.

0.00 0.00 NaN

Follow BTTX

Alert me

Market cap: $850.0K
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 19.76%

Capital & Financial Ratios $m

Market Cap 0.85

Revenue —

Net Income (31.57)

Free Cash Flow (27.40)

Net Debt 7.71

Current Ratio 0.57

Debt/Equity (1.44)

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 52.07%

Next Y EPS Growth (23.46%)

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2020	2021	2022	Q'23
Cash	0	41	16	7
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	0	0	0	0
	0	45	18	7

	2020	2021	2022	Q'23
Payables	1	2	3	2
ST’ Debt	0	—	5	7
Other	—	—	—	—
	1	5	13	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	—
Earnings	—	—	—
Book Value	—	—	—

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(5)	(6)	—	—
’22	(9)	(7)	(7)	(6)	(29)
’21	(3)	(5)	(7)	(16)	(31)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(6)	(6)	—	—
’22	(9)	(7)	(7)	(7)	(30)
’21	(3)	(5)	(7)	(16)	(32)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.39)	(0.24)	(0.15)	—	—
’22	(0.41)	(0.42)	(0.48)	(0.37)	(1.69)
’21	(0.50)	(0.81)	(1.16)	(0.71)	(3.11)

Fiscal quarters ending in the months shown.

Group	Line	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	4.41	0.91	Analyst estimates 2023–2025 Powerpack
	High	—	—	—	—	—	—	—	—	29.40	5.13
People
People	Employees	—	—	—	—	—	—	—	2	44	54
	Revenue/emp, $m	—	—	—	—	—	—	—	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	0	—	—
	Gross margin, %	—	—	—	—	—	—	—	100.00	0.00	0.00
	EBT	—	—	—	—	—	—	—	(6)	(40)	(40)
	EBT margin, %	—	—	—	—	—	—	—	(77,925.00)	0.00	0.00
	Net income	—	—	—	—	0	—	—	(6)	(40)	(40)
	Depreciation	—	—	—	—	—	—	—	0	2	3
Per share, $
Per share, $	Revenue	—	—	—	—	—	—	—	0.00	0.00	0.00
	Earnings	—	—	—	—	—	—	—	0.00	(3.11)	(1.69)
	Cash flow	—	—	—	—	—	—	—	(0.58)	(2.37)	(1.23)
	Capex	—	—	—	—	—	—	—	(0.23)	(0.08)	(0.05)
	Free cash flow	—	—	—	—	—	—	—	(0.81)	(2.46)	(1.28)
	Book value	—	—	—	—	—	—	—	(0.68)	2.83	(0.04)
	Shares, m	—	—	—	—	—	—	—	10	13	24
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	—	—
	P/S	—	—	—	—	—	—	—	0.00	—	—
	P/B	—	—	—	—	—	—	—	0.00	—	—
	EV/Sales	—	—	—	—	—	—	—	0.00	—	—
	EV/FCF	—	—	—	—	—	—	—	0.00	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	—	—	(6)	(31)	(29)
	Capex	—	—	—	—	—	—	—	(2)	(1)	(1)
	Free cash flow	—	—	—	—	—	—	—	(8)	(32)	(30)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	—	—	0	41	5
	Total debt	—	—	—	—	—	—	—	1	10	15
	Net debt	—	—	—	—	—	—	—	1	(31)	(1)
	Shareholders’ equity	—	—	—	—	—	—	—	(7)	37	(1)
Returns, %
Returns, %	ROA	—	—	—	—	—	—	—	(247.19)	(140.67)	(107.60)
	ROIC	—	—	—	—	—	—	—	0.00	(337.52)	0.00
	ROE	—	—	—	—	—	—	—	(52.69)	(269.24)	(221.99)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2020

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BBLG Bone Biologics Corp.	$1.1M	— (loss-making)	—	—	n/m	−12.97% (below 0%: shrinking)	—	0.00%	Compare
BPTH Bio-Path Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+98.68% (above 0%: growing)	0.00%	0.00%	Compare
CRIS Curis, Inc.	$1.1M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%	Compare
MNTRQ 9 Meters Biopharma, Inc.	$1.0M	— (loss-making)	—	−25.99% (below 0%: shrinking)	n/m	+0.01% (above 0%: growing)	0.00%	0.00%	Compare
ZVSA ZyVersa Therapeutics, Inc.	$970.0K	— (loss-making)	—	—	n/m	+54.91% (above 0%: growing)	0.00%	0.00%	Compare
LYRA Lyra Therapeutics, Inc.	$870.0K	— (loss-making)	— (loss-making)	−96.65% (below 0%: shrinking)	n/m	+45.44% (above 0%: growing)	100.00%	(101,685.71%)	Compare
BTTX Better Therapeutics, Inc.	$850.0K	— (loss-making)	—	—	n/m	+20.43% (above 0%: growing)	0.00%	0.00%
SEELQ Seelos Therapeutics, Inc.	$700.0K	— (loss-making)	— (loss-making)	+11.90% (above 0%: growing)	n/m	+83.54% (above 0%: growing)	100.00%	(834.84%)	Compare
ATXI Avenue Therapeutics, Inc.	$680.0K	— (loss-making)	— (loss-making)	—	n/m	−169.89% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$1.0M	—	—	−45.99%	—	+22.73%	100.00%	0.00%

All 614 Biotechnology stocks →